Star-PAP is a non-canonical, nuclear poly(A) polymerase (PAP) that is regulated by the lipid signaling molecule phosphatidylinositol 4,5 bisphosphate (PI4,5P 2 ), and is required for the expression of a select set of mRNAs. It was previously reported that a PI4,5P 2 sensitive CKI isoform, CKIa associates with and phosphorylates Star-PAP in its catalytic domain. Here, we show that the oxidative stress-induced by tBHQ treatment stimulates the CKI mediated phosphorylation of Star-PAP, which is critical for both its polyadenylation activity and stimulation by PI4,5P 2 . CKI activity was required for the expression and efficient 3 0 -end processing of its target mRNAs in vivo as well as the polyadenylation activity of Star-PAP in vitro. Specific CKI activity inhibitors (IC261 and CKI7) block in vivo Star-PAP activity, but the knockdown of CKIa did not equivalently inhibit the expression of Star-PAP targets. We show that in addition to CKIa, Star-PAP associates with another CKI isoform, CKIe in the Star-PAP complex that phosphorylates Star-PAP and complements the loss of CKIa. Knockdown of both CKI isoforms (a and e) resulted in the loss of expression and the 3 0 -end processing of Star-PAP targets similar to the CKI activity inhibitors. Our results demonstrate that CKI isoforms a and e modulate Star-PAP activity and regulates Star-PAP target messages.
INTRODUCTION
In eukaryotes, the generation of messenger RNA (mRNA) is a highly orchestrated process comprised of a number of events, including transcription, splicing, capping and 3 0 -end processing followed by export to the cytoplasm for translation (1) (2) (3) (4) . The 3 0 -end processing of mRNA precursors (pre-mRNA) is an essential step in eukaryotic gene expression which involves two tightly coupled processesendonucleolytic cleavage followed by the subsequent addition of a poly(A) tail (200-300 adenosine nucleotides) to the cleaved RNA (5) (6) (7) (8) (9) (10) (11) . The polyadenylation of mRNAs is required for their export, stability, and efficient translation (5, 10, 12) .
Polyadenylation of pre-mRNA is carried out by a class of enzymes called poly(A) polymerases (PAPs), which add a poly(A) tail to the 3 0 -end of cleaved RNA (13, 14) . PAPs function as a part of 3 0 -end processing complex (5,10) comprising of cleavage and polyadenylation specificity factors (CPSF-160, -100, -73 and -30 subunits) (15) , cleavage stimulatory factors (CstF-77, -64 and -50 subunits) (16) , cleavage factors I and II (CF I and CF II) (17, 18) , the scaffolding protein symplekin (19, 20) and poly(A) binding protein (PABP) (21) . There are multiple genes encoding PAPs in mammalian cells, including Trf4, GLD2 and PAPa, which are involved in degradation, mRNA stability, and the polyadenylation of newly transcribed mRNAs respectively (10, 22, 23) .
Star-PAP is a newly identified, nuclear PAP that is regulated by the lipid messenger phosphatidylinositol-4, 5-bisphosphate (PI4,5P 2 ). Star-PAP is required for the expression of select target messages, including heme oxygenase 1 (HO-1) (24) . Star-PAP couples to the transcriptional machinery to polyadenylate messages. Like PAPa, Star-PAP has a PAP domain and an RNA recognition motif; but the PAP domain of Star-PAP is split by a proline-rich region. Additionally, Star-PAP contains a zinc finger motif at the N-terminus (24) . Star-PAP binds its target pre-mRNA that requires both ZF and RRM domains, recruits CPSF subunits to the poly(A) site and assembles into a distinct 3 0 -end processing complex (25) .
Star-PAP 3 0 -end processing complex contains unique proteins, such as phosphatidylinositol-4-phosphate 5-kinase I alpha (PIPKIa) and the PI4,5P 2 -senstive protein kinase casein kinase Ia (CKIa) both of which are also required for the expression of some of its target mRNAs (24, 26) .
CKIa is a PI4,5P 2 -sensitive protein kinase, a member of the CKI family of Serine/Threonine (S/T) specific protein kinases (27) (28) (29) . CKIs are ubiquitous monomeric protein kinases in the size range from 35 to 55 KDa present in the membrane, nucleus, cytoplasm, cytoskeleton and spindles of mammalian cells (30, 31) . CKI phosphorylates a large number of proteins and its substrate selection in vivo is regulated by subcellular localization and/or docking sites on the specific substrate (27, 28) . CKI activity is regulated through a distinct recognition motif (S/T)(P)XX(S/T), where (S/T)(P) represents a phosphoserine or phosphothreonine residue, and the underlined S/T represents the CKI target site. This indicates that modification of serine or threonine residues by CKI requires the preceding phosphorylation of amino acid residues N-terminal of the target sequence (32) (33) (34) . CKI also phosphorylates a related unprimed site, which optimally contains a cluster of acidic amino acids N-terminal to the target S/T, including an acidic residue at N À 3 and a hydrophobic region C-terminal to the target S/T (35) (36) (37) (38) . However, for several important CKI targets such as NF-AT4 and beta-catenin, CKI does not require N À 3 priming, but instead phosphorylates the first serine in the non-canonical sequence S-L-S, which is followed by a cluster of acidic residues, albeit less efficiently than the optimal sites (39) (40) (41) . In addition, a CKI docking sequence (SDASSCE) has also been defined on the transcription factor NF-AT4 (A-2 domain), which is required for its phosphorylation (41, 42) .
There are at least four splice variants of CKIa (CK1a, CK1aS, CK1aL and CK1aLS), characterized by the presence or absence of two additional coding sequences (L or S insertions) in the catalytic domain and/or in the regulatory domain (43) (44) (45) (46) (47) . Exon 'L' encodes a 28-amino acid stretch that is inserted after lysine 152, in the center of the catalytic domain. The 'S' insert encodes 12 amino acid residues and is located close to the carboxyl terminus of the protein. The various splice isoforms of CKIa differ in their substrate preference, kinase activity, biochemical properties, subcellular localization and biological functions in the cell (28, 43, 44, 46, 47) . CKIa has been reported to associate with cytosolic vesicular structures, including small synaptic vesicles, the centrosome during interphase, and with the mitotic spindle during mitosis (30, 48) . In addition, CKIa localizes in the nucleus to nuclear speckles (26, 49) which harbor various proteins required for RNA processing and transcription (50) . Inhibitors of CKI activity, such as IC261 and CKI7, inhibit CKIa and other isoforms of CKI, including CKId and CKIe (51) . While CKI7 equally inhibits all isoforms of CKI, IC261 has higher preference to inhibit CKId and CKIe than CKIa (52) (53) (54) . These CKI isoforms have been implicated in circadian rhythm, DNA damage and various other physiological functions in the cell (51,55-57).
Previously, we have reported that Star-PAP associates with multiple kinases, including CKIa (24, 26) . Here, we show that tBHQ treatment stimulates CKI-mediated phosphorylation of Star-PAP, and that, in addition to CKIa, Star-PAP associates with another CKI isoform, CKIe in the complex, which can complement for the loss of CKIa in regulating Star-PAP activity. We demonstrate that CKI activity is necessary for in vitro Star-PAP polyadenylation activity and the 3 0 -end processing of its target messages in vivo. Our data indicate that the kinase activities of both the isoforms of CKI-a and e modulate Star-PAP polyadenylation activity and target mRNAs.
MATERIALS AND METHODS
Cell culture, transfections and cell stimulation HEK-293 and HeLa cells were obtained from ATCC and maintained in DMEM with 10% FBS at 37 C in 5% CO 2 . HeLa cells were transfected using Oligofectamine for siRNA knockdown (Invitrogen). In HEK-293 cells, transfections were accomplished by the calcium phosphate method with 5-10 mg of plasmid DNA. The knockdown of CKIa or Star-PAP was carried out as described previously (24, 26) . To induce a transcriptional antioxidant response, cells were treated for 4 h with 100 mM tertbutylhydroquinone (tBHQ) in DMSO. Control cells were treated with solvent control DMSO to a final concentration of 0.1%. The CKI activity inhibitors CKI7 (53) and IC261 (54) were dissolved in DMSO and used at a final concentration as indicated.
Expression and affinity purification of Star-PAP Affinity purified human Flag-Star-PAP was obtained from HEK-293 cells with stably expressed Flag-Star-PAP as described previously (24) . For antioxidant response, cells were treated with 100 mM tBHQ in DMSO for 4 h and DMSO for the control cells.
Protein kinase assays
Protein kinase assays were performed in a 20-ml reaction volume with 1Â kinase buffer (25 mM Tris-HCl, pH 7.5; 5 mM b-glycerol phosphate; 10 mM MgCl 2 ; 0.1 mM sodium vanadate and 0.5 mM DTT) as described previously (26) . The reaction was initiated by adding 10 mCi of g 32 P-ATP. For the inhibition studies, all reaction components except ATP were incubated with the inhibitors for 45 min on ice prior to starting the kinase assay. CKI7 or IC261 were resuspended in DMSO and used at a final concentration of 5-100 mM as indicated. Synthetic PI4,5P 2 was resuspended in 20 mM Tris-HCl, subjected to bath sonication to form micelle, and used at a concentration of 25-100 mM as indicated.
Immunoprecipitation and immunoblot analysis
Total cell lysates were prepared in buffer A [50 mM Tris (pH 7.4), 100 mM KCl, 5 mM EDTA, 5% NP-40, 5 mM NaF, 100 mg/ml RNase A, 1 mM NaVO 4 0 -RACE assay
Total RNA was extracted as described previously (24) and 3 0 -RACE was carried out as described previously (25) . The cDNAs for the 3 0 -RACE assays were synthesized using the Smart RACE Kit (Clontech) according to manufacturer's instructions with 1 mg of total RNA isolated from HEK-293 cells. The gene specific forward primers for HO-1 or GAPDH are 5 0 -GACCTGCCCAGCTCTGGC GAG-3 0 and 5 0 -GTATGACAACGAATTTGGCTACAG CAAC-3 0 . The RACE products were confirmed by sequencing.
Quantitative real-time PCR (RT-qPCR)
Total RNA was extracted and reverse transcribed as described previously (24) . Target mRNA was quantified with the MyiQ single-color real-time PCR detection system and iQ SYBR Green Supermix (Bio-Rad). Single-product amplification was confirmed by melting-curve analysis, and primer efficiency was near 100% in all experiments. Quantification is expressed in arbitrary units, and target mRNA abundance was normalized to the expression of GAPDH with the Pfaffl method. All real-time RT-qPCR results were representative of at least three independent experiments. Primers used for the PCR were CCACCAAGTTCAAGCAGC TCTA (forward) and GCTCCTGCAACTCCTCAA AGAG (reverse) for HO-1; GAAGGTCGGAGTC AAC GGATTT (forward) and GAATTTGCCATGGGTGGA AT (reverse) for GAPDH; AAGTT CTTGAAACTCTG CAAGAGAAGG (forward) and (GCCTCAACTGTATT GAACTCGGAC) for GCLC respectively.
RNA immunoprecipitation
RNA immunoprecipitation (RIP) experiments were performed as described previously (25) . The primers specific to HO-1 used to study the association of CKIa and CKIe were 5 0 -TTCTGTTGTTTTTATAGCAG-3 0 as forward and 5
0 -TCAAACAGACCAGCTCCTG-3 0 as reverse.
In vitro polyadenylation assay
In vitro polyadenylation assay with Star-PAP purified from the HEK-293 cells were performed using the 45-mer RNA oligonucleotide (UAGGGA) 5 A 15 as an RNA substrate as described previously (24) . For inhibition studies, the Star-PAP complex was isolated after the treatment of the cells with CKI inhibitors for 3 h. For the polyadenylation assay with phosphatase treatment, the samples were incubated with lamda phosphatase in RT for 30 min before the initiation of the polyadenylation reaction. Control samples were equally incubated but without phosphatase.
RESULTS
The oxidative stress agonist tBHQ stimulates Star-PAP phosphorylation Previously, it had been shown that the Flag-Star-PAP complex purified from cells retained associated kinase activity toward Star-PAP and the generic protein kinase substrates casein and myelin basic protein (MBP) (26) .
One of the associated kinases that phosphorylated Star-PAP was identified as the PI4,5P 2 -sensitive isoform of CKI, CKIa (26), but it was not clear how these kinases integrate into signaling pathways that regulate Star-PAP. Since Star-PAP purified from cells treated with the oxidative stress agonist, tert-Butylhydroquinone (tBHQ) stimulated its polyadenylation activity (24) , the effect of tBHQ treatment on the phosphorylation of Star-PAP was investigated. To assess kinase activity associated with the Star-PAP complex, the Flag-Star-PAP complex was isolated from HEK-293 cells stably expressing FlagStar-PAP after treatment with tBHQ or the DMSO solvent control. The purified Star-PAP complex was then subjected to an in vitro kinase assay using purified Star-PAP and added casein or MBP as substrates. Treatment of the cell with tBHQ stimulated a dramatic increase in the phosphorylation of Star-PAP and exogenous casein or MBP by the kinase activity associated with the cell purified Star-PAP complex ( Figure 1A ). The phosphorylation of Star-PAP increased $10-fold, whereas casein and MBP increased 3-6-fold upon tBHQ stimulation compared to the untreated samples ( Figure 1A and B). Since the previously reported Star-PAP associated kinase, CKIa is a PI4,5P 2 sensitive kinase (29), we analyzed the kinase assay in the presence of increasing concentration of PI4,5P 2 ( Figure 1C ). As previously observed, the addition of PI4,5P 2 to the kinase assay with Star-PAP purified from the unstimulated cells inhibited the phosphorylation of Star-PAP. Significant inhibition of phosphorylation was observed at 25-50 mM of PI4,5P 2 and a complete inhibition was obtained at 100 mM of PI4,5P 2 ( Figure 1C and Supplementary Figure S1A ). The stimulated phosphorylation of Star-PAP after the pre-treatment of the cell with tBHQ was equally inhibited by PI4,5P 2 . The significant inhibition of kinase activity required $50 mM of PI4,5P 2 with a complete inhibition obtainable at $100 mM ( Figure 1C and Supplementary Figure S1A ).
To confirm the role of CKI (or CKIa) in tBHQ-induced Star-PAP phosphorylation, in vitro kinase assays were carried out using the Star-PAP complex in the presence or absence of the CKI activity inhibitors CKI7 and IC261. Phosphorylation of Star-PAP was inhibited by 100 mM of either CKI7 or IC261, equally in the presence or absence of tBHQ treatment ( Figure 1D ). At higher concentration, the CKI inhibitors CKI7 and IC261 have been reported to inhibit other kinases (53, 54, 58) . To confirm that the inhibition of Star-PAP phosphorylation by CKI7 and IC261 was specific, in vitro kinase assays were further carried out with low concentrations (5-15 mM) of CKI7 and IC261. We consistently observed inhibition of Star-PAP phosphorylation equally at 10 or 15 mM of CKI7 or IC261 in presence or absence of tBHQ treatment (Supplementary Figure S2A and B) . At a concentration 5 mM of the inhibitors, there was only partial inhibition of Star-PAP phosphorylation (Supplementary Figure S2A and B). However, the association of CKIa with Star-PAP was not enhanced upon tBHQ treatment (Supplementary Figure S1B) , suggesting an increase in the kinase specific activity or association of another kinase. Taken together, these data indicate that the phosphorylation of Star-PAP mediated by CKI activity is stimulated by tBHQ treatment of the cell.
Phosphorylation of Star-PAP is critical for its polyadenylation activity
Previously, we reported that tBHQ treatment stimulated Star-PAP polyadenylation activity, and here we showed that tBHQ-induced CKI-mediated Star-PAP phosphorylation. Therefore, phosphorylation may play an important role in the regulation of Star-PAP activity. To test this, the Flag-Star-PAP complex was purified from the HEK-293 cells stably expressing Flag-Star-PAP after tBHQ treatment or solvent DMSO ( Figure 2A ). The purified Star-PAP complex was then treated with -phosphatase for 30 min at RT and then assayed for its polyadenylation activity using an A 15 RNA substrate by an in vitro polyadenylation assay (24) in the presence or absence of PI4,5P 2 . Treatment with tBHQ resulted in a dramatic stimulation of the Star-PAP polyadenylation activity upon PI4,5P 2 addition when compared to untreated cells ( Figure 2B, lane 4) , which is consistent with the previous finding that tBHQ priming is required for the stimulation of Star-PAP polyadenylation activity by PI4,5P 2 . When phosphatase treated, the purified Star-PAP complex showed minimal activity regardless of PI4,5P 2 addition or tBHQ treatment ( Figure 2B , lanes 5-8). There was a $6-fold reduction in the Star-PAP polyadenylation activity after phosphatase treatment in presence of PI4,5P 2 from tBHQ unprimed and $20-fold reduction from the tBHQ primed samples compared to that of untreated Star-PAP ( Figure 2C ). Western blot analysis showed equal amounts of Star-PAP in each reaction lane ( Figure 2C ). The loss of Star-PAP activity after phosphatase treatment indicates that phosphorylation is critical for both Star-PAP polyadenylation activity and PI4,5P 2 stimulation.
CKI activity mediated phosphorylation of Star-PAP modulates Star-PAP polyadenylation activity in vitro
Star-PAP phosphorylation is inhibited by CKI inhibitors in vitro. The expression of Star-PAP target mRNAs, such as HO-1 was also blocked after the cells were treated with CKI inhibitors (26) . To determine if CKI (or CKIa) is the critical kinase regulating Star-PAP activity, the FlagStar-PAP complex was purified from the HEK-293 cells stably expressing Flag-Star-PAP following the Figure S3B) . The purified Star-PAP complex (Supplementary Figure S3B) was then subjected to in vitro polyadenylation assays (24) . Star-PAP purified from the CKIa inhibitor treated cells (CKI7 and IC261) diminished the Star-PAP polyadenylation activity compared to the control cells ( Figure 3A and D) . There was little polyadenylation activity, which failed to be stimulated by tBHQ treatment or the addition of PI4,5P 2 ( Figure 3D, lanes 1-8) . The addition of the CKI inhibitors (CKI7 and IC261) to the polyadenylation reaction, however, did not affect the Star-PAP polyadenylation activity (data not shown). The loss of CKIa had a modest effect on the Star-PAP polyadenylation activity and was less efficient in the inhibition of Star-PAP polyadenylation activity compared to the CKI inhibitor treatments ( Figure 3B and D) consistent with the previous observation (26) . The addition of PI4,5P 2 and/or tBHQ pre-treatment did show significant enhancement of the polyadenylation ( Figure 3B) . Additionally, the Flag-Star-PAP complex purified from cells transiently expressing a Star-PAP mutant with a deletion within the proline rich region (residues 223-274) (26), exhibited no polyadenylation activity ( Figure 3C ). Taken together, these data suggest that phosphorylation of Star-PAP by CKI modulates the Star-PAP polyadenylation activity downstream of stimulation by oxidant stress and phosphorylation primes Star-PAP, so that it can be stimulated by PI4,5P 2 .
CKI activity is required for the efficient 3 0 -end processing and expression of Star-PAP target mRNAs in vivo
We have shown that CKIa phosphorylates Star-PAP and modulates Star-PAP's polyadenylation activity. To further examine the role of CKI activity in the expression and 3
0 -end processing of Star-PAP target messages, total RNA was isolated from HEK-293 cells after transfection with siRNA (control siRNA or siRNA specific for Star-PAP or the associated kinase CKIa) ( Figure 4D and E for western) or treatment with the CKI inhibitor IC261 in the presence and absence of tBHQ stimulation of the cells. We then analyzed the total mRNA expression and the measure of 3 0 -end processed (polyadenylated, mature) mRNA of Star-PAP direct target heme oxygenase-1 (HO-1) by RT-qPCR and 3 0 -RACE assay, respectively. As expected, RT-qPCR demonstrated an induction of $15-fold of HO-1 expression after tBHQ treatment and knockdown of endogenous Star-PAP or treatment with CKI inhibitor IC261 ablated both basal and stress-induced HO-1 mRNA levels ( Figure 4A) (24, 26) . Knockdown of CKIa did not inhibit tBHQ-induced HO-1 message unlike the CKI inhibitor, IC261, which efficiently blocked the tBHQ-induced HO-1 expression ( Figure 4A ) (26) . The expression of the Star-PAP non-target glutamate-cysteine ligase, catalytic subunit (GCLC) was not affected by tBHQ treatment, CKIa knockdown, or CKI inhibitor treatments ( Figure 4B ).
To further examine the role of CKI activity in the 3 0 -end processing of HO-1 pre-mRNA, the knockdown and inhibitor approach described above was employed, followed by 3 0 -RACE analysis from the total RNA to measure the mature polyadenylated mRNA in the cell. Distinct RACE products for HO-1 ($700 bp in length) were observed in control cells with a large induction upon tBHQ stimulation. HO-1 production was lost after the inhibition of cellular CKI activity with IC261, demonstrating that CKI activity is necessary for the processing of this Star-PAP target mRNA ( Figure 4C) . Consistent with the expression profile, CKIa knockdown was not effective in blocking the 3 0 -end processed (polyadenylated) mRNA after tBHQ stimulation ( Figure 4C ). The non-target glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was not affected by tBHQ treatment, CKIa knockdown, or CKI inhibitor treatment ( Figure 4C ). These results suggest that CKI activity is required for the expression of Star-PAP target and that Star-PAP complex perhaps contains other isoforms of CKI in addition to CKIa. Star-PAP is an essential factor for the cleavage of its target mRNA and Star-PAP recruits the cleavage factors to the pre-mRNA (25) . Therefore, we measured the HO-1 uncleaved mRNA levels to study the possible role of CKI activity in the cleavage of Star-PAP target pre-mRNAs. Consistent with the previous report (24) , Star-PAP knockdown resulted in $12-fold increase in the quantity of uncleaved HO-1 mRNA relative to total HO-1 mRNA ( Figure 4F ). Loss of CKIa or treatment with IC261 did not exhibit any significant change in the cleavage of HO-1 pre-mRNA ( Figure 4F) ; suggesting that the regulation Star-PAP target messages by CKI activity regulates polyadenylation. Similarly, the association and assembly of Star-PAP polyadenylaton complex did not appear to be affected by CKI activity as demonstrated by western analysis of key Star-PAP associated factors after the inhibition of CKI in the cell (Supplementary Figure S4A) .
Another CKI isoform, CKIe associates with and phosphorylates Star-PAP
CKIa knockdown only partially blocked the basal expression of HO-1 (26) and poorly blocked tBHQ stimulated Star-PAP polyadenylation activity and the expression of Star-PAP targets. Therefore it is possible that Star-PAP complex associates with additional isoforms of CKI that compensate for the loss of CKIa. To test this hypothesis, we knocked down CKIa from the cell and isolated the Flag-Star-PAP complex and subjected it to kinase assay with casein as a substrate. We observed that even after the knock down of CKIa, significant amount of kinase activity was still associated with the Star-PAP complex toward casein, which was equally-induced by tBHQ treatment similar to the wild type cells ( Figure 5A ). This suggests that Star-PAP complex contains additional casein kinase(s) other than CKIa. Since, the kinase inhibitors IC261 and CKI7 employed for our study also inhibits CKIe and d (51) in addition to CKIa (26), we tested the association of these isoforms in the Flag-purified Star-PAP complex from the cell in the presence or absence of tBHQ treatment. We observed the association of CKIe but not d in the Star-PAP complex purified from cells both with tBHQ treatment and without tBHQ treatment ( Figure 5B ). Other casein kinases such as CKII did not associate with the Star-PAP complex ( Figure 5B ). Control protein, b-tubulin was also not detected in the Star-PAP complex purified from the cell (Figure 5B ), suggesting the specificity of the proteins associated with the Star-PAP complex.
We further investigated if CKIe phosphorylates Star-PAP by an in vitro kinase assay. GST-tagged recombinant full length CKIe was tested for its ability to phosphorylate the heat inactivated Flag-tagged Star-PAP isolated from the cell or His-tagged recombinant Star-PAP. We also tested the activity of GST-CKIe with its generic kinase substrate casein (Supplementary Figure S4B) . We observed the phosphorylation of both cell-purified (Flag-tagged) ( Figure 5D ) and recombinant (His-tagged) ( Figure 5E ) Star-PAP by CKIe. There was a dose dependent increase in phosphorylation with increased CKIe concentration for both the substrates ( Figure 5D and E). The control Flag-tagged CKIa also phosphorylated the heat inactivated cell-purified FlagStar-PAP ( Figure 5C ) as previously described (26) . These results indicate that the associated CKIe can directly phosphorylate Star-PAP.
Since CKIa phosphorylates Star-PAP in the proline rich region, which splits the catalytic domain, we tested if CKIe also shares the similar region of phosphorylation on Star-PAP. Kinase assays were performed to test the activity of GST-tagged CKIe toward Flag-purified Star-PAP with deletion of the proline rich region, with CKIa as control. As expected, both CKIa and CKIe exhibited kinase activity toward full length (FL) Flag-Star-PAP ( Figure 5F ). Remarkably, the GST-CKIe failed to phosphorylate the Star-PAP with deletion of proline rich region (ÁPRR) like CKIa, while there was intact phosphorylation of full length Star-PAP ( Figure 5F ). This suggests that both isoforms (a and e) share similar region of phosphorylation on Star-PAP.
CKI isoforms a and e are required for the stressed induced expression of Star-PAP target mRNA
Since CKIe phosphorylates Star-PAP and shares the similar region of phosphorylation with CKIa, we investigated if CKIe has any role in the regulation of Star-PAP target messages. RT-qPCR analysis was performed with total RNAs isolated from cells after the single knockdowns of CKIa and CKIe or together in the presence or absence of tBHQ treatment ( Figure 6D for western). Consistent with above observations, there was no loss of oxidative stress-induced expression after CKIa knockdown ( Figure 6A) . Similarly, CKIe knockdown did not significantly impact tBHQ-induced expression of HO-1 mRNA ( Figure 6A ). However, strikingly, when both the isoforms (CKIa and CKIe) were knocked down together, this blocked the expression of HO-1 ( Figure 6A ) demonstrating that both kinases regulate expression of the Star-PAP target HO-1, or that the two isoforms have redundant function to regulate Star-PAP. The control mRNA GCLC was not affected by either single or double knockdowns of CKIa and CKIe ( Figure 6B) .
Similarly, by the 3 0 -RACE assay which measures the mature polyadenylated message from the cell, we observed distinct signals from control resting cells, stimulated by tBHQ treatment that were lost upon the knockdown of Star-PAP ( Figure 6C ) as previously described (25) . Consistent with the total mRNA levels, there was no significant reduction in the RACE products upon CKIa or CKIe knockdowns in presence of tBHQ treatment compared to the control samples ( Figure 6C ). Yet, when both isoforms (a and e) were knocked down, there was complete loss of the RACE product corroborating the above observation that CKIa and CKIe are required for the expression of Star-PAP target mRNA. The control non-target GAPDH was not affected by either single or double knockdowns of CKIa and CKIe ( Figure 6C ).
Star-PAP is a PAP that binds to pre-mRNA along with other cleavage factors, assembling a distinct processing complex on the 3 0 -end of its target RNAs (25) . In addition, CKIa associates with HO-1 pre-mRNA (26) perhaps by virtue of its interaction with Star-PAP 3 0 -end processing complex. Therefore, we investigated if CKIe exhibits association with HO-1 pre-mRNA by an RIP experiment. The cells were cross-linked with formaldehyde and IP'ed using the respective antibodies followed by detection of the associated RNA by RT-PCR using primers specific to HO-1 3 0 -UTR. As expected, we saw the association of Star-PAP and CKIa similar to the control RNA Pol II ( Figure 6E ). Interestingly, we also observed the association of CKIe with HO-1 3 0 -UTR RNA ( Figure 6E ) supporting the above observations that CKIe also acts as a part of Star-PAP 3 0 -end processing complex. Figure 7 . Gonzales et al. (26) showed that the CKIa phosphorylation site within the PRR of Star-PAP interrupts the catalytic domain and this implied that phosphorylation of Star-PAP could affect its enzymatic activity. Here, we show that in addition to CKIa, CKIe also phosphorylates Star-PAP in a similar region in the catalytic domain. This phosphorylation modulates Star-PAP polyadenylation activity and the expression of the Star-PAP target HO-1. Similar regulation of PAP activity by phosphorylation was also reported for canonical PAPa (59, 60) , although the mechanism of regulation is different. These differences can be attributed to the distinct kinases and stimuli responsible for the phosphorylation of the two polymerases (59) . PAPa is phosphorylated at the C-terminal end by ERK kinase, whereas Star-PAP is phosphorylated within the catalytic region by both CKIa and CKIe (24, 59, 60) . Inhibition of PAPa phosphorylation resulted in a loss of polyadenylation activity. Star-PAP phosphorylation is required for both polyadenylation activity and its stimulation by PI4,5P 2 . Since Star-PAP activity is specifically regulated by PI4,5P 2 binding, an inhibition in activity may indicate that the PI4,5P 2 binding site overlaps with the CKI phosphorylation sites or be regulated indirectly (24) . These data indicate that phosphorylation modulates substrate recognition, PI4,5P 2 binding or both to regulate Star-PAP activity. The proline rich region in the catalytic domain where both CKIa and e phosphorylate Star-PAP contains a cluster of about 15 Ser/Thr residues which are putative sites for CKI phosphorylation. Therefore, it is likely that there is a complex phosphorylation pattern involving multiple sites that are common or overlapping for both the CKI isoforms. Both the phosphorylation of Star-PAP by CKI isoforms and Star-PAP activity are regulated by oxidative stress. Yet, the association of CKIa or CKIe with Star-PAP did not increase upon stimulation with oxidative stress, suggesting that enhanced CKI kinase activity was responsible for the increase in Star-PAP activity. The mechanism of oxidant-induced CKI-regulated Star-PAP activity remains elusive. CKI isoforms act as a downstream target of oxidative stress signal; however, the current literature indicates that members of the CKI family are constitutively active kinases (49) . Alternatively, an oxidative stress signal may induce yet-to-be-identified nuclear factors that cooperate with CKIa or CKIe to induce the phosphorylation of Star-PAP. One similar example is the phosphorylation of mammalian IFNARI by CKIa, which is greatly induced by ER stress (61) .
DISCUSSION
CKIa or e are regulated by hierarchical priming in that they can require prior phosphorylation by other protein kinases to generate their substrate site for phosphorylation (27) . The CKI isoforms also spatially integrate into protein complexes and this modulates their activity toward proteins in those complexes (27, 28, 49) . Both of these properties may influence CKI control of Star-PAP function. There are additional protein kinases that associate with the Star-PAP complex that are stimulated by oxidative stress and these may define the hierarchical priming of CKI isoforms for Star-PAP phosphorylation and activity. The kinase that phosphorylates MBP has not yet been identified, but may be a protein kinase that defines hierarchical priming of the associated CKI protein kinases.
Star-PAP regulation is integrated into multiple signaling pathways (62) . Different Star-PAP target genes are specifically modulated by distinct signaling pathways individually or synergistically (62) . In addition, Star-PAP-dependent mRNAs are specific to a select set of messages (24) (25) (26) . However, it is still unclear how the Star-PAP dependent 3 0 -end processing complex identifies the target mRNAs (25, 62) . One possibility is the direct interaction of Star-PAP with certain sequence elements on its target mRNAs as evidenced by its footprint on the target HO-1 mRNA (25) . Phosphorylation of Star-PAP at distinct sites by various protein kinases could also determine the target gene specificity or the signaling to regulate Star-PAP. Moreover, the Star-PAP 3 0 -end processing complex associates with PIPKIa (24) and protein kinases including CKIa and CKIe. It has been reported that PIPKIa or CKIa are required for the expression of some but not all Star-PAP target mRNAs (24, 26) . Therefore, such proteins could also be involved in modulating Star-PAP target specificity in addition to regulating its polyadenylation activity.
